{"id":"W2947026438","doi":"10.1200/jco.2019.37.15_suppl.6000","title":"Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Carboplatin; Population; Head and neck squamous-cell carcinoma; Pembrolizumab; Internal medicine; Interim analysis; Cisplatin; Oncology; Head and neck cancer; Urology; Nuclear medicine; Radiation therapy; Randomized controlled trial; Surgery; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002956322,0.0002216616,0.002494437,0.0002870047,0.00004915103,0.00000863786,0.0002933016,0.0002781429,0.0004062734],"category_scores_gemma":[0.001037396,0.0001285359,0.00183416,0.0005164907,0.0003218477,0.00007090739,0.00004136473,0.0005776922,0.000001393106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001038135,"about_ca_system_score_gemma":0.001624158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005265082,"about_ca_topic_score_gemma":0.00007366473,"domain_scores_codex":[0.9949431,0.0005244924,0.003509236,0.0002728476,0.0004953989,0.0002549353],"domain_scores_gemma":[0.9918463,0.003066589,0.00392339,0.0004211795,0.0005637101,0.0001787931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8959373,0.008069726,0.009284534,0.0002416306,0.001366789,0.0000189544,0.0001811416,0.00001786792,0.001457796,0.00002182714,0.0009655537,0.0824369],"study_design_scores_gemma":[0.6317196,0.2018028,0.07705034,0.0001160903,0.002335088,0.00006046983,0.0000871486,0.0006318841,0.001804873,0.0001502274,0.08409066,0.000150772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.977633,0.0004753502,0.0000688263,0.002106164,0.0009093439,0.01829771,0.00003589322,0.000003594379,0.0004701128],"genre_scores_gemma":[0.9968789,0.0003006025,0.0006707556,0.0006724821,0.0004648129,0.0006580906,0.000006148642,0.00002126332,0.0003269321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2642177,"threshold_uncertainty_score":0.5241542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1809768907209643,"score_gpt":0.4906753055908003,"score_spread":0.309698414869836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}